相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Xanthine oxidase inhibition attenuates doxorubicin-induced cardiotoxicity in mice
Yoshiro Tanaka et al.
FREE RADICAL BIOLOGY AND MEDICINE (2021)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
Kerstin N. Timm et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
Milton Packer
DIABETES CARE (2020)
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Claire C. J. Dekkers et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Jolanda Sabatino et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: In Vitro and Molecular Docking Studies
Shenouda G. Eliaa et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Echocardiographic Strain Analysis for the Early Detection of Left Ventricular Systolic/Diastolic Dysfunction and Dyssynchrony in a Mouse Model of Physiological Aging
Claudio de Lucia et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2019)
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Chenguang Li et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Ferroptosis as a target for protection against cardiomyopathy
Xuexian Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity
Akira Yoshii et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
Chih-Chao Yang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Chang-Myung Oh et al.
KOREAN CIRCULATION JOURNAL (2019)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2018)
Improving the quality of preclinical research echocardiography: observations, training, and guidelines for measurement
Daniel G. Donner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2018)
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
Bernard Zinman et al.
DIABETOLOGIA (2018)
Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme
Manlio Barbarisi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use
Mia Baxter-Holland et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2018)
Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
Gennaro Riccio et al.
FRONTIERS IN PHYSIOLOGY (2018)
Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity
Vincenzo Quagliariello et al.
NUTRIENTS (2018)
Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
Kwong-Man Ng et al.
SCIENTIFIC REPORTS (2018)
Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
Maria C. Arciniegas Calle et al.
BMC CANCER (2018)
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormone-Responsive Human Breast Cancer
Vincenzo Quagliariello et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and nondiabetic populations: a systematic review and meta-analysis
Ivan Cavero-Redondo et al.
BMJ OPEN (2017)
Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study
Bruno Cesar Bacchiega et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
Ioanna Andreadou et al.
FRONTIERS IN PHYSIOLOGY (2017)
Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy
Xinqiang Han et al.
NPJ PRECISION ONCOLOGY (2017)
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
Elza Muscelli et al.
DIABETOLOGIA (2016)
AMP18 interacts with the anion exchanger SLC26A3 and enhances its expression in gastric cancer cells
Chiara Stella Di Stadio et al.
BIOCHIMIE (2016)
Doxorubicin-Induced Systemic Inflammation Is Driven by Upregulation of Toll-Like Receptor TLR4 and Endotoxin Leakage
Lintao Wang et al.
CANCER RESEARCH (2016)
Pathophysiology of anthracycline cardiotoxicity
Donato Mele et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2016)
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors
Nicola Maurea et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2016)
Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity
Michela Pecoraro et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2016)
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking
Carmela Coppola et al.
ONCOTARGETS AND THERAPY (2016)
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus
Irene Romera et al.
ENDOCRINOLOGIA Y NUTRICION (2016)
Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus: A Review of the Evidence
John R. White
ANNALS OF PHARMACOTHERAPY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparative Myocardial Deformation in 3 Myocardial Layers in Mice by Speckle Tracking Echocardiography
Nicole Tee et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction
Carlo G. Tocchetti et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Yoshihiko Ichikawa et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells
H. Kim et al.
BRITISH JOURNAL OF CANCER (2013)
A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors
Leo Mascarenhas et al.
PEDIATRIC BLOOD & CANCER (2013)
Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse
Stefano Toldo et al.
PLOS ONE (2013)
Exposing cardiomyocytes to subclinical concentrations of doxorubicin rapidly reduces their creatine transport
Marcus D. Darrabie et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2012)
Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo
Hiromichi Nakabayashi et al.
BMC CANCER (2012)
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
Carmine Fedele et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Heloisa Sawaya et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2012)
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Yanti Octavia et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Heloisa Sawaya et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity
Jinzhou Zhu et al.
BIOMEDICINE & PHARMACOTHERAPY (2011)
Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome
Kristin A. D. Sauter et al.
CANCER BIOLOGY & THERAPY (2011)
Right Ventricular Dysfunction following Acute Myocardial Infarction in the Absence of Pulmonary Hypertension in the Mouse
Stefano Toldo et al.
PLOS ONE (2011)
Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity
Jinzhou Zhu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Murine echocardiography and ultrasound imaging
Andrew Pistner et al.
Jove-Journal of Visualized Experiments (2010)
Interleukin 8 and cardiovascular disease
Stavros Apostolakis et al.
CARDIOVASCULAR RESEARCH (2009)
Topoisomerase IIβ-Mediated DNA double-strand breaks:: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane
Yi Lisa Lyu et al.
CANCER RESEARCH (2007)
Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes
S Hrelia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2002)
Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation
E Aldieri et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2002)
Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase - Effect of antiapoptotic antioxidants and calcium
SV Kalivendi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy
MM Sayed-Ahmed et al.
PHARMACOLOGY & TOXICOLOGY (2001)
分享论文
